Literature DB >> 6600932

N-terminal amino acid sequences of the alpha and beta chains of HLA-DR1 and HLA-DR2 antigens.

L E Walker, R Hewick, M W Hunkapiller, L E Hood, W J Dreyer, R A Reisfeld.   

Abstract

The N-terminal amino acid sequences of the alpha and beta chains of HLA-DR1 and HLA-DR2 antigens were obtained with subnanomole quantities of material by using a gas-liquid solid-phase sequencer. A comparison of the N-terminal amino acid sequences of HLA-DR1 and HLA-DR2 alpha chains revealed no differences. However, in the first 35 N-terminal residues of the beta chains from HLA-DR1 and HLA-DR2 antigens, two regions of variability are readily apparent, each comprising about six amino acids. Conceivably one or both of these variability regions may be responsible for the serologically defined polymorphism of HLA-DR alloantigens.

Mesh:

Substances:

Year:  1983        PMID: 6600932     DOI: 10.1021/bi00270a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?

Authors:  I Le Gall; P Millasseau; J Dausset; D Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  DNA sequence and characterization of human class II major histocompatibility complex beta chains from the DR1 haplotype.

Authors:  J I Bell; P Estess; T St John; R Saiki; D L Watling; H A Erlich; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

3.  Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition.

Authors:  H L Niman; R A Houghten; L E Walker; R A Reisfeld; I A Wilson; J M Hogle; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

4.  Characterization of three HLA-DR beta genes isolated from an HLA-DR 3/4 insulin-dependent diabetic patient.

Authors:  D Owerbach; C Rich; K Taneja
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.